Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination

Nuclear Medicine and Biology

Volumn 33, Issue 4, 2006, Pages 453-458

  Laverman, Peter ^a   de Vries, I Jolanda M ^b   Scharenborg, Nicole M ^b   de Boer, Annemiek ^b   Broekema, Matthias ^a   Oyen, Wim J G ^a   Figdor, Carl G ^b   Adema, Gosse J ^b   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; DTPA conjugation; Immunotherapy; Peptides

Indexed keywords

DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INDIUM 111; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PENTETIC ACID; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; CANCER VACCINE; DIAGNOSTIC AGENT; INDIUM; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BINDING AFFINITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CONJUGATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IC 50; IMMUNOPRECIPITATION; ISOTOPE LABELING; LYMPHOBLASTOID CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; RADIOACTIVITY; VACCINATION; BINDING SITE; IMMUNOLOGY; PROTEIN BINDING; SCINTISCANNING; TRANSPLANTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; HLA-A2 ANTIGEN; HUMANS; INDIUM RADIOISOTOPES; PEPTIDES; PROTEIN BINDING; RADIOPHARMACEUTICALS;

EID: 33646586985     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.02.005     Document Type: Article

References (12)

1. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
2. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9 (2003) 5091-5100
3. de Vries I.J., Krooshoop D.J., Scharenborg N.M., Lesterhuis W.J., Diepstra J.H., Van Muijen G., et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63 (2003) 12-17
4. van der Burg S.H., Ras E., Drijfhout J.W., Benckhuijsen W.E., Bremers A.J., Melief C.J., et al. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol 44 (1995) 189-198
5. Lev A., Denkberg G., Cohen C.J., Tzukerman M., Skorecki K.L., Chames P., et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62 (2002) 3184-3194
6. Denkberg G., Cohen C.J., Lev A., Chames P., Hoogenboom H.R., and Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A 99 (2002) 9421-9426
7. Sette A., Sidney J., Del Guercio M.F., Southwood S., Ruppert J., Dahlberg C., et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 31 (1994) 813-822
8. Bakker A.B., Schreurs M.W., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179 (1994) 1005-1009
9. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157 (1996) 2539-2548
10. de Vries I.J., Bernsen M.R., Lesterhuis W.J., Scharenborg N.M., Strijk S.P., Gerritsen M.J., et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23 (2005) 5779-5787
11. Latron F., Pazmany L., Morrison J., Moots R., Saper M.A., McMichael A., et al. A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells. Science 257 (1992) 964-967
12. Ljunggren H.G., Stam N.J., Ohlen C., Neefjes J.J., Hoglund P., Heemels M.T., et al. Empty MHC class I molecules come out in the cold. Nature 346 (1990) 476-480